Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Healthcare · OQB
Fundamentals
Valuation and ratings
Reviva Pharmaceuticals Holdings, Inc. trades at USD0.47, which is 120% below the USD1.04 our discounted cash flow model puts on the business. On that measure alone it screens as undervalued, though a DCF is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 10 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
RVPH earnings and analyst estimates
Recommendation mix, 1 analyst rating
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
RVPH passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
3 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$579.3K · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$31.4K · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$7.8K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is Reviva Pharmaceuticals Holdings, Inc. (RVPH) undervalued?
Against our discounted cash flow estimate of USD1.04, RVPH at USD0.47 is 120% below fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
Which funds own RVPH?
3 of the institutions we track reported a position in RVPH in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
When does RVPH report earnings next?
Reviva Pharmaceuticals Holdings, Inc. is scheduled to report on 13 Aug 2026. Companies move earnings dates, so read it as scheduled rather than certain.
The full research page for RVPH, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.